Because Recce Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. Generally speaking, companies ...

Search Engine Land » Platforms » Apple » Apple Maps » Recce Offers Winning Take On 3D Mapping Share The most interesting development in digital maps may not in fact be the forthcoming ...

Recce’s synthetic anti-infective treated a range of skin infections in a mid-stage trial, setting the Australian biotech’s sights on a phase 3 trial.

Recce Pharmaceuticals Ltd (ASX:RCE) is aiming to complete a capital raising of $15.8 million to funds its clinical trials in Indonesia and Australia through a $5M Placement to a private investor ...

Special Report: Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives RECCE® 327 (R327) and RECCE® 529 (R529) as it targets the growing global health ...

Recce Pharmaceuticals Ltd (ASX:RCE) successfully passed a resolution via poll at their Special General Meeting, marking a significant step in their strategic initiatives. The company is known for ...

RECCE® 327 Topical Gel (R327G) was demonstrated to be safe and well-tolerated in patients – R327G demonstrating highly encouraging efficacy results as determined by non-Data Safety Monitoring ...

Recce secures full entitlement shortfall to complete $15.8m raise for phase III clinical trials Recce receives firm commitments to place the full shortfall from its entitlement offer raising a ...

Recce Pharmaceuticals Ltd’s recent Annual General Meeting saw all proposed resolutions passed, showcasing strong shareholder support. The company’s innovative pipeline of synthetic anti ...

Shortfall placement concludes Recce’s $15.8 million capital raising to support phase III clinical trials in Indonesia and Australia Following the equity raise Recce will have a pro-forma cash ...